SHANGHAI and HONG
KONG, Nov. 5, 2024 /PRNewswire/ -- Antengene
Corporation Limited ("Antengene", SEHK: 6996.HK), a leading
innovative, commercial-stage global biopharmaceutical company
dedicated to discovering, developing and commercializing
first-in-class and/or best-in-class medicines for cancer, today
announced that it will present results from three programs at
the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC
2024) to be held in Houston,
the United States from
November 6-10, 2024.
Details of Poster Presentations:
ATG-201 (CD19 x
CD3 T-cell Engager)
Title: ATG-201, a novel
"2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B
cell malignancies and B cell related autoimmune diseases
Abstract Number: 1067
Poster Abstract Presentation at the SITC Immune Engineering
Workshop
Date: November 7, 2024
Time: 3:10 PM - 5:00 PM (Central
Standard Time)
5:10 AM - 7:00 AM, Nov 8,
2024 (Beijing Time)
Poster Presentation at the SITC 39th Annual
Meeting
Date: November 8, 2024
Time: 9:00 AM - 7:00 PM (Central
Standard Time)
11:00 PM, Nov 8 - 9:00 AM, Nov 9,
2024 (Beijing Time)
- CD19-targeted therapies like CAR-T and T-cell engagers (TCEs)
are used for B-cell malignancies, with early success in autoimmune
diseases like SLE. However, TCEs face challenges due to
pharmacokinetics and cytokine release syndrome (CRS). ATG-201, a
"2+1" CD19 x CD3 TCE, was developed to address these issues.
- ATG-201 binds to CD19+ cells with high affinity, limiting CD3
binding and T cell activation before CD19 crosslinking, reducing
the risk of CRS. It demonstrated strong B-cell depletion and
anti-lymphoma efficacy in preclinical studies with lower cytokine
release compared to other benchmarks.
- ATG-201 demonstrated deep and durable depletion of tissue
resident B cells in mice and showed potent in vivo efficacy
in models for autoimmune diseases (MS, SLE).
- ATG-201 presents a potential therapeutic option for B-cell
malignancies and autoimmune diseases, offering CD19-dependent
T-cell activation and effective B-cell depletion with a low risk of
CRS.
ATG-107 (FLT3 x CD3 T-cell Engager)
Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE)
targeting FLT3, demonstrates potent preclinical efficacy for the
treatment of AML
Abstract Number: 1068
Poster Abstract Presentation at the SITC Immune Engineering
Workshop
Date: November 7, 2024
Time: 3:10 PM - 5:00 PM (Central
Standard Time)
5:10 AM - 7:00 AM, Nov 8,
2024 (Beijing Time)
Poster Presentation at the SITC 39th Annual
Meeting
Date: November 9, 2024
Time: 9:00 AM - 8:30 PM (Central
Standard Time)
11:00 PM, Nov 9 - 10:30 AM, Nov 10,
2024 (Beijing Time)
- Acute myeloid leukemia (AML) is the most common acute leukemia
with poor treatment outcomes. FLT3 is over expressed in over 80% of
AML cases, while its expression on normal hematopoietic stem cells
is low. A novel 2+1 FLT3 x CD3 TCE, ATG-107, was developed to
target FLT3, redirecting T-cells to attack AML cells.
- ATG-107 binds bivalently to FLT3, concealing the CD3 binding
site until FLT3 is engaged. Preclinical studies showed strong
T-cell activation and cytotoxicity against AML cells, regardless of
FLT3 mutation status, and potent in vivo anti-AML efficacy
in PBMC humanized mouse models.
- ATG-107 presents a promising therapeutic strategy for a broad
AML patient population, offering FLT3-dependent T-cell activation
and potent preclinical efficacy.
ATG-106 (CDH6 x CD3 T-cell Engager)
Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell
Engager (TCE), shows potent T cell dependent cytotoxicity and in
vivo anti-tumor efficacy
Abstract Number: 1069
Poster Presentation at the SITC 39th Annual
Meeting
Date: November 8, 2024
Time: 9:00 AM - 7:00 PM (Central
Standard Time)
11:00 PM, Nov 8 - 9:00 AM, Nov 9,
2024 (Beijing Time)
- CDH6 is a type II cadherin protein involved in
calcium-dependent cell-cell adhesion, and its overexpression has
been identified in several cancer types, including ovarian cancer,
renal cell carcinoma, and thyroid cancer.
- ATG-106, a "2+1" CDH6 x CD3 TCE, was designed to address CRS
challenge by targeting CDH6 and activating T cells only in the
presence of CDH6-positive cells, minimizing CRS risk. Preclinical
studies showed strong binding affinity to CDH6+ cells and potent
T-cell-dependent cytotoxicity. It induced lower cytokine release
in vitro compared to benchmarks.
- In vivo studies using ovarian cancer xenograft models
demonstrated that ATG-106 achieved significant tumor growth
inhibition (TGI) with tumor shrinkage and complete remission
observed in multiple treatment groups.
- ATG-106 exhibited strong anti-tumor efficacy and T-cell
activation in preclinical ovarian cancer models, supporting its
potential for further clinical evaluation.
About the AnTenGager™ Platform
The AnTenGager™ Platform is a proprietary "2+1" T cell engager
(TCE) platform developed by Antengene. AnTenGager™ TCE
simultaneously binds to disease-associated antigens (targets) and a
unique conformational epitope on CD3 that expressed on T-cells. The
bivalent binding to the targets enables detection and depletion of
cells with low expression of the targets. In addition, AnTenGager™
TCE activates T cells in a target-dependent manner so that it
demonstrates a lower risk of systemic CD3 activation and cytokine
release syndrome (CRS), potentially paving the way for their use in
autoimmune diseases, hematological malignancies, and solid
tumors.
Our extensive and diverse pipeline features promising TCEs that
aim to address unmet medical needs in autoimmune diseases and
hematology/oncology, with best-in-class/first-in-class potential. A
few of our lead programs in the IND-enabling stage include ATG-201,
a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a
LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic
myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian
cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and
ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS)
colorectal cancer.
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading
commercial-stage R&D-driven global biopharmaceutical company
focused on the discovery, development, manufacturing and
commercialization of innovative first-in-class/best-in-class
therapeutics for the treatment of hematologic malignancies and
solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets
at various stages going from clinical to commercial, including 6
with global rights, and 3 with rights for the APAC region. To date,
Antengene has obtained 31 investigational new drug (IND) approvals
in the U.S. and Asia, and
submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for
XPOVIO® (selinexor)
already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only
to the events or information as of the date on which the statements
are made in this article. Except as required by law, we undertake
no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to
reflect the occurrence of unanticipated events. You should read
this article completely and with the understanding that our actual
future results or performance may be materially different from what
we expect. In this article, statements of, or references to, our
intentions or those of any of our Directors or our Company are made
as of the date of this article. Any of these intentions may alter
in light of future development. For a further discussion of these
and other factors that could cause future results to differ
materially from any forward-looking statement, please see the other
risks and uncertainties described in the Company's Annual Report
for the year ended December 31, 2023,
and the documents subsequently submitted to the Hong Kong Stock
Exchange.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000
View original content to download
multimedia:https://www.prnewswire.com/news-releases/antengene-presents-results-from-three-investigational-programs-at-the-2024-sitc-annual-meeting-302296416.html
SOURCE Antengene Corporation Limited